Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus

Blood (2022) 140 (Supplement 1): 8932–8933.

https://doi.org/10.1182/blood-2022-170376

Published: 2022

Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2021) 138 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2021-146182

Published: 2021

Journal Articles

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

Deborah M. Stephens, Hongli Li, Louis S. Constine, John P. Leonard, Brad S. Kahl, Joo Y Song, Michael L. Leblanc, Thomas J. Fitzgerald, Sonali M. Smith, Jonathan W. Friedberg, Dan O. Persky

Blood (2021) 138 (Supplement 1): 1423.

https://doi.org/10.1182/blood-2021-147938

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136422

Published: 2020

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Diana G Adlowitz, PhD, Janice M Spence, PhD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 2771.

https://doi.org/10.1182/blood-2019-121632

Published: 2019

Journal Articles

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Janice M Spence, PhD, Diana Adlowitz, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 919.

https://doi.org/10.1182/blood-2018-99-111399

Published: 2018

Journal Articles

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Deborah M. Stephens, Hongli Li, MS, Heiko Schoder, MD, David J. Straus, MD, Craig H. Moskowitz, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Ann S. LaCasce, MD MSc, Paul Barr, MD, Michael V. Knopp, Eric D. Hsi, MD, John P. Leonard, MD, Brad S Kahl, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 929.

https://doi.org/10.1182/blood-2018-99-113034

Published: 2018

Journal Articles

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Chul S. Ha, MD, Hongli Li, MS, Heiko Schoder, MD, Chelsea C Pinnix, MD, Elizabeth Brem, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Eric D. Hsi, MD, Lisa M. Rimsza, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Louis S. Constine, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2018-99-113133

Published: 2018

Journal Articles

Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma

Manali Kamdar, MD, Hongli Li, MS, Robert W. Chen, MD, Lisa M. Rimsza, MD, Michael L. Leblanc, PhD, Timothy S. Fenske, MD, Paul Barr, MD, Tycel J. Phillips, MD, John P. Leonard, MD, Brad S Kahl, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2018) 132 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2018-99-112752

Published: 2018

Journal Articles

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Eric D. Hsi, MD, Hongli Li, MS, Andrew B. Nixon, PhD, Andrew M Evens, DO,MSc, Heiko Schoder, MD, David J. Straus, MD, Nancy L. Bartlett, MD, John William Sweetenham, MDFRCP, Paul M. Barr, MD, Michelle A. Fanale, MD, James R. Cook, MD PhD, Brad S Kahl, MD, John P. Leonard, MD, Sonali M. Smith, MD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 4033.

https://doi.org/10.1182/blood.V130.Suppl_1.4033.4033

Published: 2017

Journal Articles

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Deborah M. Stephens, DO, Hongli Li, MS, Daniel Persky, MD, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Carla Casulo, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 4122.

https://doi.org/10.1182/blood.V130.Suppl_1.4122.4122

Published: 2017

Journal Articles

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Xiaoyu Qu, PhD, Hongli Li, MS, Oliver W. Press, MD PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Michael L. Leblanc, PhD, Eric D. Hsi, MD, John P. Leonard, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD, Min Fang, MDPhD

Blood (2017) 130 (Supplement 1): 1507.

https://doi.org/10.1182/blood.V130.Suppl_1.1507.1507

Published: 2017

Journal Articles

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Daniel Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 1553.

https://doi.org/10.1182/blood.V130.Suppl_1.1553.1553

Published: 2017

Journal Articles

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Heather L. Tardif, Song Yao, PhD, Bryan H. Goldman, MS, Catherine M. Spier, MD, Michael L. LeBlanc, PhD, Lisa M. Rimsza, MD, Daniel O. Persky, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Christine B. Ambrosone, PhD, Margaret M. Briehl, PhD

Blood (2010) 116 (21): 321.

https://doi.org/10.1182/blood.V116.21.321.321

Published: 2010

Journal Articles

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Lisa M. Rimsza, Michael L. LeBlanc, Joseph M. Unger, Thomas P. Miller, Thomas M. Grogan, Daniel O. Persky, Ralph R. Martel, Constantine M. Sabalos, Bruce Seligmann, Rita M. Braziel, Elias Campo, Andreas Rosenwald, Joseph M. Connors, Laurie H. Sehn, Nathalie Johnson, Randy D. Gascoyne

Blood (2008) 112 (8): 3425–3433.

https://doi.org/10.1182/blood-2008-02-137372

Published: 2008

Includes: Supplemental data

Journal Articles

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Lisa M. Rimsza, MD, Michael L. LeBlanc, PhD, Robin A. Roberts, BS, Joseph M. Unger, MS, Thomas P. Miller, MD, Constantine M. Sabalos, MS, Ralph R. Martel, PhD, Elias Campo, MD, Andreas Rosenwald, MD, Joseph M. Connors, MD, Laurie H. Sehn, MD, Natalie Johnson, MD, Randy D. Gascoyne, MD

Blood (2007) 110 (11): 50.

https://doi.org/10.1182/blood.V110.11.50.50

Published: 2007

Journal Articles

Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin’s Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438).

John A. Thompson, MD, Richard I. Fisher, MD, Michael L. LeBlanc, PhD, Joseph M. Unger, MS, Stephen J. Forman, MD, Patrick J. Stiff, MD, Alexander Fefer, MD

Blood (2006) 108 (11): 326.

https://doi.org/10.1182/blood.V108.11.326.326

Published: 2006

NARROW

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592)

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only